

MDA2016-08-02 - Dose Assignment/Intervention Administration Data Dictionary

TABLE OF CONTENTS

Document Summary.....	2
MDA2016-08-02 - Dose Assignment/Intervention Administration: Data Dictionary	3
Section 1: Identifiers	3
Section 2: Study-wide	4
Section 3: Dose Assignment/Intervention Administration	5

Document Summary

Property	Value
Document Title	MDA2016-08-02 - Dose Assignment/Intervention Administration: Data Dictionary
Date Created	06/29/2023
Sections	3
Entries	18
Document Filename	dictionary_doseassigninterventionadmin.rtf

MDA2016-08-02 - Dose Assignment/Intervention Administration: Data Dictionary

Section 1: Identifiers

Class	Variable	Label	Description	Format Text
01. Principal	MRNO	MRNO		Char

Section 2: Study-wide

Class	Variable	Label	Description	Format Text
01. Principal	Accession	Accession Number		Numeric
01. Principal	Form	Form		"Dose Assignment/Intervention Admin"="Dose Assignment/Intervention Admin"
01. Principal	Institution	Registering Institution		"M. D. Anderson Cancer Center"="M. D. Anderson Cancer Center"
01. Principal	Interval	Interval		"Event Interval not available"="Event Interval not available"
01. Principal	Interval_Date	Interval Date		SAS Date
01. Principal	Reg_Date	Registering Date		Char
01. Principal	Trial	Trial		"MDA2016-08-02"="MDA2016-08-02"

Section 3: Dose Assignment/Intervention Administration

Class	Variable	Label	Description	Format Text
01. Principal	_233_10025_Date_Agent_Provided_t	Date Agent Provided To Participant		Char
01. Principal	_233_10026_Date_Agent_Started	Date Agent Started		Char
01. Principal	_233_12574_Screen_2_Date_NA	Screen 2 Date Not Applicable		"False"="False" "True"="True"
01. Principal	_233_12575_Screen_2_Date	Screen 2 Date		Char
01. Principal	_233_12576_Enrollment_Date	Enrollment Date		Char
01. Principal	_233_14517_TAC	Treatment Assignment Code (TAC)		"TAC1"="TAC1" "TAC2"="TAC2" "TAC3"="TAC3" "TAC4"="TAC4"
01. Principal	_233_14517_TAC_Desc_	Treatment Assignment Code (TAC) (Desc)		"TAC1: Bexarotene 1% gel 10 mg applied topically to one unaffected breast QOD x 4 weeks"="TAC1: Bexarotene 1% gel 10 mg applied topically to one unaffected breast QOD x 4 weeks" "TAC2: Bexarotene 1% gel 10 mg applied topically to one unaffected breast QOD x 7 days, then QD x 3 weeks"="TAC2: Bexarotene 1% gel 10 mg applied topically to one unaffected breast QOD x 7 days, then QD x 3 weeks" "TAC3: Bexarotene 1% gel 10 mg applied topically to one unaffected breast QOD x 7 days, then 10 mg QD x 1 week, then 20 mg QD x 2 weeks"="TAC3: Bexarotene 1% gel 10 mg applied topically to one unaffected breast QOD x 7 days, then 10 mg QD x 1 week, then 20 mg QD x 2 weeks" "TAC4: Bexarotene 1 % gel MTD applied topically to one unaffected breast x 4 weeks"="TAC4: Bexarotene 1 % gel MTD applied topically to one unaffected breast x 4 weeks"
01. Principal	_233_14526_Is_participant_eligib0	Is Participant Eligible For Inclusion On This Protocol 1		"No"="No" "Yes"="Yes"
01. Principal	_233_14526_Is_participant_eligib	Is Participant Eligible For Inclusion On This Protocol		"No"="No" "Yes"="Yes"
01. Principal	_233_14527_Participant_Assigned_	Participant Assigned To Receive		"TAC1"="TAC1" "TAC2"="TAC2" "TAC3"="TAC3" "TAC4"="TAC4"

